 |
|
Should Corticosteroids Be Considered as Part of the Standard Care With Photodynamic Therapy?
Arch Ophthalmol. 2006;124:563-571.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Why are physicians interested in combining intravitreal triamcinolone with verteporfin photodynamic therapy (PDT)? Visual outcome with verteporfin PDT is poor. Nonetheless, among patients with age-related macular degeneration (AMD) and predominantly classic or pure occult choroidal new vessels (CNVs), verteporfin PDT increases one's chance of losing fewer than 15 letters on a Bailey-Lovie eye chart by approximately 40% during a 2-year follow-up, compared with sham treatment.1-2 The Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy (VIP) studies, both of which were randomized, placebo-controlled multicenter clinical trials, identified few treatment-related adverse events. In the TAP study, these included transient visual disturbances (in 22% vs 16% of controls), injection site complications (in 16% vs 6% of controls), transient photosensitivity reactions (in 3.5% vs 0% of controls), severe visual loss within 1 week of therapy (in 0.75% vs 0% of controls), and infusion-related back pain (in 2% vs . . . [Full Text of this Article]
DISEASES ASSOCIATED WITH ABNORMAL VASCULAR PERMEABILITY AND RETINAL NEOVASCULARIZATION
NON-AMD–ASSOCIATED CNVs NONRANDOMIZED STUDIES OF AMD EYES RANDOMIZED STUDIES OF AMD EYES ENDOPHTHALMITIS INCREASED INTRAOCULAR PRESSURE CATARACT
AUTHOR INFORMATION
Marco Zarbin, MD, PhD
Author Affiliations: Institute of Ophthalmology and Visual Science, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
